Sorrento Therapeutics, Inc (Nasdaq: SRNE) is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Cancers are genetically diverse, highly adaptive, constantly mutating and virtually invisible to the immune system. Therefore, we believe any single target therapy is destined to fail. Our approach to cancer therapy is based ...
Sorrento Therapeutics, Inc (Nasdaq: SRNE) is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Cancers are genetically diverse, highly adaptive, constantly mutating and virtually invisible to the immune system. Therefore, we believe any single target therapy is destined to fail. Our approach to cancer therapy is based on the belief that patients will require a multimodal, multipronged approach – targeting a single or diverse set of cellular targets.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.